Loading...
In the ACCORD study of patients with type 2 diabetes (mean age, 62; average duration of diabetes, 10 years), intensive glycemic control led to excess mortality and did not lower the incidence of adverse cardiovascular events (JW Gen Med Jun 6 2008). Moreover, in the ACCORD Lipid and Blood Pressure substudies, neither fenofibrate nor intensive antihypertensive therapy resulted in fewer adverse cardiovascular outcomes (JW Cardiol Mar 14 2010 #1 and JW Cardiol Mar 14 2010 #2).
Now, ACCORD researchers present retinopathy outcomes in 2856 patients. The primary endpoint was a 3-step change on a 17-step retinopathy scale (determined from serial retinal photographs) or development of proliferative retinopathy requiring photocoagulation or vitrectomy…